New Alliance Capital is a venture capital and private equity firm founded in 2008 and headquartered in Shanghai, China. The firm specializes in early-stage, growth-stage, and pre-IPO investments across a diverse range of sectors, including high-end manufacturing, technology, advanced agriculture, consumer goods, information, media, energy, recycling, environmental protection, and modern services. New Alliance typically invests amounts ranging from approximately $4.71 million to $31.41 million. In addition to its investments in China, the firm also focuses on private equity opportunities in the United States, particularly in the technology, media, and telecommunications (TMT), cultural media, healthcare, and energy sectors.
Infervision is an artificial intelligence company based in Beijing that specializes in enhancing medical imaging diagnosis through deep learning and computer vision technologies. The company focuses on developing clinically valuable products aimed at improving the accuracy and efficiency of cancer diagnosis. Infervision has introduced innovative solutions such as the world's first artificial intelligence precise healthcare platform, along with intelligent X-ray and CT diagnostic products, which are currently undergoing trials at several prominent hospitals in China. The company collaborates closely with top institutions in radiology, fostering a strong relationship between medical science and technology. Infervision has partnered with approximately 20 leading hospitals, successfully integrating medical data and technology to advance healthcare solutions. By creating a unique artificial intelligence computing platform, Infervision aims to facilitate precise healthcare and improve diagnostic outcomes for medical professionals.
CapitalBio Technology Co., Ltd. is a life science company based in Beijing, China, specializing in the development and commercialization of healthcare solutions. Founded in 2012, it offers a wide range of products including nucleic acid detection kits for respiratory pathogens and Hepatitis B virus, as well as a Thalassemia gene mutations detection kit. The company also provides microarray and microfluidic chips, along with related instruments, software, reagents, and consumables for various applications such as clinical diagnostics, drug development, and molecular breeding. Additionally, CapitalBio Technology offers services including SNP analysis, mRNA expression profiling, DNA methylation detection, and sequencing. As a subsidiary of CapitalBio Corporation, the company is equipped with over 35,000 square meters of office space and employs more than 500 staff members, the majority of whom hold advanced degrees.
Beijing Advaccine Biotechnology Co., Ltd. is a biotechnology company dedicated to the discovery and development of innovative vaccines, both preventive and therapeutic. The company's product pipeline includes vaccines targeting respiratory syncytial virus (RSV), hepatitis B virus (HBV), and a therapeutic vaccine for type 1 diabetes (T1D). Advaccine's research focuses on addressing unmet clinical needs globally, with an emphasis on first-in-class products. The company aims to enhance patient care by inducing immuno-tolerance and stimulating T-cell responses for specific diseases. Based in Beijing, China, Advaccine is committed to advancing viral vaccine technology to improve health outcomes.
CapitalBio Technology Co., Ltd. is a life science company based in Beijing, China, specializing in the development and commercialization of healthcare solutions. Founded in 2012, it offers a wide range of products including nucleic acid detection kits for respiratory pathogens and Hepatitis B virus, as well as a Thalassemia gene mutations detection kit. The company also provides microarray and microfluidic chips, along with related instruments, software, reagents, and consumables for various applications such as clinical diagnostics, drug development, and molecular breeding. Additionally, CapitalBio Technology offers services including SNP analysis, mRNA expression profiling, DNA methylation detection, and sequencing. As a subsidiary of CapitalBio Corporation, the company is equipped with over 35,000 square meters of office space and employs more than 500 staff members, the majority of whom hold advanced degrees.
CapitalBio Technology Co., Ltd. is a life science company based in Beijing, China, specializing in the development and commercialization of healthcare solutions. Founded in 2012, it offers a wide range of products including nucleic acid detection kits for respiratory pathogens and Hepatitis B virus, as well as a Thalassemia gene mutations detection kit. The company also provides microarray and microfluidic chips, along with related instruments, software, reagents, and consumables for various applications such as clinical diagnostics, drug development, and molecular breeding. Additionally, CapitalBio Technology offers services including SNP analysis, mRNA expression profiling, DNA methylation detection, and sequencing. As a subsidiary of CapitalBio Corporation, the company is equipped with over 35,000 square meters of office space and employs more than 500 staff members, the majority of whom hold advanced degrees.
Beijing Advaccine Biotechnology Co., Ltd. is a biotechnology company dedicated to the discovery and development of innovative vaccines, both preventive and therapeutic. The company's product pipeline includes vaccines targeting respiratory syncytial virus (RSV), hepatitis B virus (HBV), and a therapeutic vaccine for type 1 diabetes (T1D). Advaccine's research focuses on addressing unmet clinical needs globally, with an emphasis on first-in-class products. The company aims to enhance patient care by inducing immuno-tolerance and stimulating T-cell responses for specific diseases. Based in Beijing, China, Advaccine is committed to advancing viral vaccine technology to improve health outcomes.
Beijing Deepwise Science And Technology Co., Ltd. develops an artificial intelligence (AI) based medical application software that provides clinical imaging analysis and clinical diagnostics. The company offers early screening and diagnosis of various malignant diseases. It serves to hospitals, medical centers, and third party imaging centers. The company was founded in 2017 and is based in Beijing, China.
CooTek (NYSE: CTK), founded in 2008, listed on NYSE on September 28th, 2018, is a global and fast-growing mobile internet company that develops innovative mobile apps and artificial intelligence technology. With a massive global user base, CooTek aims to empower users to express themselves and enjoy relevant content seamlessly. CooTek’s flagship mobile app, TouchPal Keyboard, uses unparalleled technology to provide the best input experience to both Android and iPhone users. CooTek has also developed many content-rich apps, spanning across 5 selected verticals including fitness, lifestyle, healthcare, news and short videos, and entertainment. In September 2018, CooTek’s global products reached an average of 213.7 million monthly active users around the world. Headquartered in Shanghai, CooTek offices can be found in Silicon Valley, Beijing, Taipei, Guangzhou, and Shenzhen. Today, CooTek has over 170 patent applications and granted patents worldwide and continually pursue excellence in technology innovation and intellectual property development. CooTek has also established its own big data development center and AI lab in Silicon Valley. Many academic papers written by CooTek have been used in discussions at world-renowned big data and AI conferences such as AAAI, KDD and CIKM.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.